Birdwatch Note
2024-11-02 01:40:28 UTC - MISINFORMED_OR_POTENTIALLY_MISLEADING
副反応の程度と長期的な安全性は別の話です。 接種に伴う副反応は、一般的に軽度かつ一過性で、多くは数日以内に収まります。 https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/vaccine_qa.html#25 https://www.skmg.jp/kasukabe-kosei/department/pharmacy/covid19/ https://www.kyushu-u.ac.jp/ja/researches/view/734/ 重篤な副反応は10万人に1人程度で稀です。 https://www.igakuken.or.jp/r-info/covid-19-info75.html https://www.niid.go.jp/niid/images/plan/kisyo/2022/22-2-4.pdf ワクチンの長期的な影響は不明な点もありますが、体内に遺伝情報が取り入れられることはなく、現時点で長期的な影響は認められていません。 https://www3.nhk.or.jp/news/special/coronavirus/vaccine/qa/detail/more-detail/qa_05_a09.html 一方でCOVID-19への感染は重篤な疾患や長期的な障害を引き起こすことが既に知られています。 https://www.jrs.or.jp/covid19/faq/vaccine/20221019000001.html https://www.pmda.go.jp/int-activities/int-harmony/icmra/0029.html ワクチンは重症化予防効果などが高く評価されており、多くで接種するメリットが接種しないデメリットを上回ります。 https://www.tm.nagasaki-u.ac.jp/versus/results/20230725.html https://www.kansensho.or.jp/uploads/files/guidelines/2112_covid-19_4.pdf https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/vaccine_yuukousei_anzensei.html https://www.niid.go.jp/niid/ja/2019-ncov/2484-idsc/10966-covid19-71.html
Written by 5E1F2EF85D85AA5362909FF226739D1E3A39DD99C7CFB2D1FC2819611D8ED82A
Participant Details
Original Tweet
Tweet embedding is no longer reliably available, due to the platform's instability (in terms of both technology and policy). If the Tweet still exists, you can view it here: https://twitter.com/foo_bar/status/1852319532997902386
Please note, though, that you may need to have your own Twitter account to access that page. I am currently exploring options for archiving Tweet data in a post-API context.
All Information
- ID - 1852526157075513547
- noteId - 1852526157075513547
- participantId -
- noteAuthorParticipantId - 5E1F2EF85D85AA5362909FF226739D1E3A39DD99C7CFB2D1FC2819611D8ED82A Participant Details
- createdAtMillis - 1730511628776
- tweetId - 1852319532997902386
- classification - MISINFORMED_OR_POTENTIALLY_MISLEADING
- believable -
- harmful -
- validationDifficulty -
- misleadingOther - 0
- misleadingFactualError - 1
- misleadingManipulatedMedia - 0
- misleadingOutdatedInformation - 0
- misleadingMissingImportantContext - 0
- misleadingUnverifiedClaimAsFact - 0
- misleadingSatire - 0
- notMisleadingOther - 0
- notMisleadingFactuallyCorrect - 0
- notMisleadingOutdatedButNotWhenWritten - 0
- notMisleadingClearlySatire - 0
- notMisleadingPersonalOpinion - 0
- trustworthySources - 1
- summary
- 副反応の程度と長期的な安全性は別の話です。 接種に伴う副反応は、一般的に軽度かつ一過性で、多くは数日以内に収まります。 https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/vaccine_qa.html#25 https://www.skmg.jp/kasukabe-kosei/department/pharmacy/covid19/ https://www.kyushu-u.ac.jp/ja/researches/view/734/ 重篤な副反応は10万人に1人程度で稀です。 https://www.igakuken.or.jp/r-info/covid-19-info75.html https://www.niid.go.jp/niid/images/plan/kisyo/2022/22-2-4.pdf ワクチンの長期的な影響は不明な点もありますが、体内に遺伝情報が取り入れられることはなく、現時点で長期的な影響は認められていません。 https://www3.nhk.or.jp/news/special/coronavirus/vaccine/qa/detail/more-detail/qa_05_a09.html 一方でCOVID-19への感染は重篤な疾患や長期的な障害を引き起こすことが既に知られています。 https://www.jrs.or.jp/covid19/faq/vaccine/20221019000001.html https://www.pmda.go.jp/int-activities/int-harmony/icmra/0029.html ワクチンは重症化予防効果などが高く評価されており、多くで接種するメリットが接種しないデメリットを上回ります。 https://www.tm.nagasaki-u.ac.jp/versus/results/20230725.html https://www.kansensho.or.jp/uploads/files/guidelines/2112_covid-19_4.pdf https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/vaccine_yuukousei_anzensei.html https://www.niid.go.jp/niid/ja/2019-ncov/2484-idsc/10966-covid19-71.html
Note Ratings
rated at | rated by | |
2024-11-02 16:31:04 -0500 | Rating Details | |
2024-11-02 06:32:48 -0500 | Rating Details | |
2024-11-02 02:59:01 -0500 | Rating Details | |
2024-11-02 00:41:57 -0500 | Rating Details | |
2024-11-02 00:20:45 -0500 | Rating Details | |
2024-11-02 00:16:24 -0500 | Rating Details | |
2024-11-02 00:12:43 -0500 | Rating Details | |
2024-11-01 23:08:11 -0500 | Rating Details | |
2024-11-01 23:04:31 -0500 | Rating Details | |
2024-11-01 22:10:24 -0500 | Rating Details | |
2024-11-01 22:00:46 -0500 | Rating Details | |
2024-11-01 21:36:29 -0500 | Rating Details | |
2024-11-01 21:11:10 -0500 | Rating Details | |
2024-11-03 01:18:04 -0600 | Rating Details | |
2024-11-02 20:55:28 -0500 | Rating Details | |
2024-11-02 20:45:01 -0500 | Rating Details | |
2024-11-02 12:13:50 -0500 | Rating Details | |
2024-11-02 10:55:53 -0500 | Rating Details | |
2024-11-02 09:16:23 -0500 | Rating Details | |
2024-11-02 05:20:41 -0500 | Rating Details | |
2024-11-02 05:06:33 -0500 | Rating Details | |
2024-11-02 04:43:29 -0500 | Rating Details | |
2024-11-02 04:20:40 -0500 | Rating Details | |
2024-11-02 02:23:46 -0500 | Rating Details | |
2024-11-02 01:24:19 -0500 | Rating Details | |
2024-11-02 00:00:45 -0500 | Rating Details | |
2024-11-01 23:31:53 -0500 | Rating Details | |
2024-11-01 21:49:09 -0500 | Rating Details | |
2024-11-01 21:23:21 -0500 | Rating Details | |
2024-11-04 13:26:09 -0600 | Rating Details | |
2024-11-04 00:43:28 -0600 | Rating Details | |
2024-11-02 10:03:04 -0500 | Rating Details | |
2024-11-02 06:36:11 -0500 | Rating Details | |
2024-11-02 06:34:01 -0500 | Rating Details | |
2024-11-02 06:03:14 -0500 | Rating Details | |
2024-11-02 05:10:29 -0500 | Rating Details | |
2024-11-02 04:57:51 -0500 | Rating Details | |
2024-11-02 02:56:19 -0500 | Rating Details | |
2024-11-02 00:52:32 -0500 | Rating Details | |
2024-11-02 00:47:49 -0500 | Rating Details | |
2024-11-01 23:47:50 -0500 | Rating Details | |
2024-11-01 23:42:54 -0500 | Rating Details | |
2024-11-01 23:29:19 -0500 | Rating Details | |
2024-11-01 23:19:13 -0500 | Rating Details | |
2024-11-01 21:51:30 -0500 | Rating Details | |
2024-11-01 21:12:27 -0500 | Rating Details | |
2024-11-05 07:44:29 -0600 | Rating Details | |
2024-11-03 22:51:02 -0600 | Rating Details | |
2024-11-03 02:00:59 -0600 | Rating Details | |
2024-11-02 04:56:29 -0500 | Rating Details | |
2024-11-02 01:45:06 -0500 | Rating Details | |
2024-11-02 01:28:59 -0500 | Rating Details | |
2024-11-02 01:28:14 -0500 | Rating Details | |
2024-11-02 01:16:42 -0500 | Rating Details | |
2024-11-02 01:08:12 -0500 | Rating Details | |
2024-11-02 00:08:51 -0500 | Rating Details | |
2024-11-01 23:31:49 -0500 | Rating Details | |
2024-11-01 23:01:33 -0500 | Rating Details | |
2024-11-01 22:21:04 -0500 | Rating Details | |
2024-11-01 21:13:55 -0500 | Rating Details | |
2024-11-04 06:20:43 -0600 | Rating Details | |
2024-11-02 21:03:53 -0500 | Rating Details | |
2024-11-02 07:16:11 -0500 | Rating Details | |
2024-11-02 06:20:59 -0500 | Rating Details | |
2024-11-02 03:40:12 -0500 | Rating Details | |
2024-11-02 03:20:37 -0500 | Rating Details | |
2024-11-02 02:05:16 -0500 | Rating Details | |
2024-11-02 01:48:17 -0500 | Rating Details | |
2024-11-02 01:18:18 -0500 | Rating Details | |
2024-11-01 22:10:21 -0500 | Rating Details | |
2024-11-01 21:41:48 -0500 | Rating Details | |
2024-11-01 21:41:23 -0500 | Rating Details | |
2024-11-01 21:37:28 -0500 | Rating Details |